Voyager Therapeutics Inc logo

Voyager Therapeutics Inc

$ 8.10 -0.78 (-8.78%) 11:08 PM EST
P/E:
At Loss
P/B:
3.91
Market Cap:
$ 312.72M
Enterprise V:
$ 204.85M
Volume:
560.08K
Avg Vol (2M):
392.88K
Also Trade In:
Volume:
560.08K
Market Cap $:
312.72M
PE Ratio:
At Loss
Avg Vol (2-Month):
392.88K
Enterprise Value $:
204.85M
PB Ratio:
3.91

Business Description

Description
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
Name Current Vs Industry Vs History
Cash-To-Debt 5.54
Equity-to-Asset 0.44
Debt-to-Equity 0.3
Debt-to-EBITDA -1.73
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.44
Distress
Grey
Safe
Beneish M-Score 0.56
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 23.37
9-Day RSI 39.65
14-Day RSI 48.05
6-1 Month Momentum % -14.85
12-1 Month Momentum % 100.67

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.01
Quick Ratio 2.01
Cash Ratio 1.8
Days Sales Outstanding 12.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5.4